Moderna Aktie News

Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday.

Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine developed in collaboration with Merck, which yielded encouraging outcomes in minimizing melanoma recurrence when paired with Keytruda immunotherapy.

Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential.

Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.

Moderna's and Merck's partnership could help to advance cancer care. A promising skin cancer trial might have broader implications for other types of tumor treatments.

In a blast from the past, COVID-19 vaccine developer Moderna NASDAQ: MRNA just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three years.

Moderna and Merck's cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.